Company Overview

MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on the development of targeted cancer therapies. The company operates within the oncology and biopharmaceutical research and development industries, with a scientific emphasis on telomere-targeting mechanisms as a novel approach to treating cancer. MAIA’s core strategy is centered on advancing differentiated therapies for difficult-to-treat malignancies where unmet medical need remains high.

The company’s primary product candidate is THIO (6-thio-dG), an investigational small-molecule drug designed to selectively target cancer cell telomeres and induce tumor cell death while sparing normal cells. MAIA primarily serves the oncology clinical and research market, including patients with advanced solid tumors. Its unique positioning lies in its telomere-focused therapeutic platform, which represents a mechanistically distinct alternative to traditional chemotherapy and immuno-oncology approaches. MAIA was formed to translate academic telomere science into commercial oncology applications and has since evolved into a publicly traded clinical-stage company advancing human trials.

Business Operations

MAIA operates as a single-reportable-segment biotechnology company, focused exclusively on oncology drug development. The company does not generate commercial revenue and instead relies on capital raised through equity offerings to fund research and development activities. Its operations include preclinical research, clinical trial execution, regulatory engagement, and manufacturing oversight through third-party providers.

The company’s activities are primarily conducted in the United States, with international clinical trial participation in Europe. MAIA does not currently market approved products and does not operate manufacturing facilities, instead utilizing contract research organizations and clinical partners. Public disclosures indicate no material revenue-producing subsidiaries; the business is managed as an integrated R&D organization focused on advancing THIO through clinical development.

Strategic Position & Investments

MAIA’s strategic direction is centered on advancing THIO through mid-stage clinical trials for multiple oncology indications, including lung and other solid tumors. Growth initiatives are focused on expanding clinical data, pursuing regulatory pathways, and exploring combination therapy potential with existing cancer treatments. The company emphasizes capital efficiency and targeted trial design to demonstrate proof-of-concept and clinical differentiation.

The company has not disclosed any material acquisitions or diversified investment holdings. Strategic investments are primarily internal, directed toward clinical trial execution, intellectual property protection, and regulatory preparation. MAIA’s portfolio is concentrated, with THIO representing its principal asset, and no additional late-stage pipeline candidates have been publicly confirmed. Data regarding additional platform technologies beyond telomere targeting is inconclusive based on available public sources.

Geographic Footprint

MAIA is headquartered in the United States, with corporate operations based in Illinois. Its clinical development activities extend internationally through trial sites and research collaborators in Europe, supporting patient enrollment and regulatory engagement outside the U.S.

The company’s geographic presence is primarily operational rather than commercial, reflecting its clinical-stage status. MAIA does not report material revenue from any geographic region and does not maintain sales or marketing infrastructure globally. Its international footprint is driven by research needs and access to specialized oncology centers rather than by market distribution.

Leadership & Governance

MAIA is led by an executive team with experience in biotechnology, oncology drug development, and capital markets. The leadership philosophy emphasizes scientific rigor, disciplined clinical development, and shareholder alignment through focused asset advancement.

Key executives include:

• Vlad Vitoc – Chief Executive Officer
• David Mack – Chief Financial Officer
• Thomas P. Krenitsky – Chief Medical Officer

Information regarding founders and additional executive officers beyond those listed above is limited; data inconclusive based on available public sources. The company operates under a standard public-company governance structure with oversight from its board of directors, consistent with U.S. listed biotechnology firms.